Literature DB >> 20194244

Cost-effectiveness of biologics in early rheumatoid arthritis.

Axel Finckh, Nick Bansback, Matthew H Liang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20194244     DOI： 10.7326/0003-4819-152-5-201003020-00018

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  3 in total

1.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.

Authors:  Jinoos Yazdany; Gabriela Schmajuk; Mark Robbins; David Daikh; Ashley Beall; Edward Yelin; Jennifer Barton; Adam Carlson; Mary Margaretten; Joann Zell; Lianne S Gensler; Victoria Kelly; Kenneth Saag; Charles King
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

3.  Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation--an economic analysis based on the ESPOIR cohort.

Authors:  Karine Chevreul; Georges Haour; Sandy Lucier; Stephanie Harvard; Marie-Laure Laroche; Xavier Mariette; Alain Saraux; Isabelle Durand-Zaleski; Francis Guillemin; Bruno Fautrel
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.